Pfizer is dedicated to investing in healthcare. This investment is demonstrated by the development and production of high-quality medical products across a wide range of therapy areas, and through involvement in initiatives for healthcare professionals, patients, carers and the general public.

Pfizer is a leader in the development and manufacturing of innovative and high-quality biologic medicines that help meet the needs of patients and advance standards of care. We are committed to advancing science and developing innovative biologics that aim to address significant unmet medical needs. Building on our expertise in biologics, and in addition to our regulatory, commercial and manufacturing strengths, Pfizer is working to advance high-quality, well tolerated and effective biosimilars that provide patients and prescribers with additional treatment options. 

With 30 years of experience manufacturing recombinant DNA products and significant expertise in the clinical development of novel products in many therapeutic areas, Pfizer is well positioned to meet the demand for manufacturing high-quality biosimilars. 

The development of biologic therapies has introduced many additional treatments for a variety of conditions over a range of therapeutic areas including Oncology.¹  The introduction of biosimilars have increased the number of therapeutic options available to healthcare professional, providing cost-effective treatment options with a range of additional benefits and features.²

Prescribing Information for Great Britain and Northern Ireland:

 

References
1. Sekhon BH and Saluja V. Biosimilars 2011; 1:1-11. 
2. Peeters M, et al. Future Oncology 2021; 17(29): 3881-3892.